Miz1: How early endotoxin exposure could guard against allergic asthma and how we might use that idea to help patients
Official title: Miz1: Mechanistic Insights into Endotoxin-Induced Protection Against Allergenic Asthma and Its Therapeutic Potential
Funded at University of Illinois at Chicago · NIH-11420529 · Data updated 2026-11-12
A study exploring how a molecule called Miz1 changes with early endotoxin exposure to reduce allergic asthma, with potential to lead to new prevention or treatment options for people with asthma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project start | September 23, 2025 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $783,416 |
| NIH project number | 5R01HL181375-02 |
| Project ID | NIH-11420529 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with or at risk for allergic asthma, and patients of any age affected by allergic triggers, may be relevant for future clinical translation or biomarker studies.
✕Less likely to help
Individuals unlikely to benefit are those without asthma or allergic sensitivity and not part of translational efforts.
What this research studies
This project looks at why early exposure to certain microbes might protect some children from developing allergic asthma. It will study Miz1, a protein that may be turned down by endotoxin and help shield against asthma, using lab models and analyses of human samples. The researchers will examine how endotoxin affects Miz1 at the molecular level, and how this change influences allergy-related inflammation. They will also test whether targeting the Miz1 pathway could prevent or lessen asthma in experimental models and investigate whether this pathway is altered in allergen-exposed humans with asthma.
Why it matters
Potential benefit: If successful, the work could reveal new ways to prevent or treat allergic asthma by modulating the Miz1 pathway.
How similar studies have gone: Prior research suggests endotoxin exposure can influence asthma risk, but precise Miz1-related mechanisms are still being explored, making this approach promising yet exploratory.
Where this research is happening
-
University of Illinois at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Liu, Jing — University of Illinois at Chicago
- Study coordinator: Liu, Jing
Related research
Other NIH-funded projects on the same topics.
-
GLP-1 receptor agonists as immune targets to treat asthma in lean and obese adults
Aims to understand how GLP-1R‑agonist diabetes medicines may directly calm immune cells to reduce asthma in adults who are lean or obese.
-
Understanding how a type of immune cell called ILC2s affect asthma in adults
This grant studies how group 2 innate lymphoid cells influence asthma in adults to help identify new ways to manage airway inflammation.
-
Expanding understanding of asthma in kids through airways and blood profiling
A study at UC San Francisco will profile blood and nasal/sputum samples from 300 youth (including 200 with asthma) over a year to understand how environmental and social factors influence asthma in marginalized communities.
-
Preventing and improving asthma care for children in urban communities
This program will try several approaches — from giving helpful bacteria to babies to allergy immunotherapy and advanced airway testing — to prevent and better treat asthma in children who live in cities.
-
IDEAL project helps predict vaccine response, infections, and asthma in early childhood
A Child-focused program will collect and share saliva, blood, and tissue samples from diverse infants to find biological patterns that predict how vaccines work, how respiratory infections occur, and who develops asthma.
-
Understanding how early-life immune development affects vaccine responses and asthma risk in children
This project uses lab-grown human immune cells from infants and young children to explore why some kids respond poorly to vaccines and are more prone to respiratory infections and asthma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.